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  EVIDENCE-BASED ANSWER 
Postherpetic neuralgia occurs rarely among patients aged <50 years with herpes zoster. The incidence, 
duration, and severity of post-herpetic neuralgia increases with age, but older patients usually have only mild 
pain. Most cases resolve spontaneously within 3 months.1,2 
Even in the highest-risk group, people aged >70 years, 25% had some pain at 3 months, but only 10% had 
pain at 1 year, and none had severe pain. Only a few patients have pain that persists for years (strength of 
recommendation: A, based on a well-done prospective cohort study). 
  EVIDENCE SUMMARY 
Postherpetic neuralgia is defined as pain that persists more than 1 month following onset of herpes zoster. The 
annual incidence of herpes zoster in population-based studies ranges from 1/1000 to 2/1000.1,3 Among adults 
aged >60 years, the annual incidence increases to 3.6/1000 for men and 5.6/1000 for women.1 
In a prospective study performed in a primary care setting in Iceland, all cases of herpes zoster and 
postherpetic neuralgia occurring over 4.5 years in a population of 100,000 were identified, and all cases of 
postherpetic neuralgia were followed for up to 7.6 years. Few patients (4%) received antiviral medication. 
In this study, postherpetic neuralgia followed herpes zoster in 2% of patients under age 40, 21% between the 
ages of 40 and 60, and in 40% of those over age 60.1,2 Subjects self-described pain as none, mild, moderate, 
or severe. Patients aged >60 years had the worst prognosis: 18% still had mild pain at 3 months and 6% had 
moderate or severe pain. At 1 year, 8% had mild pain and 2% had moderate pain. No patients had severe pain 
after 12 months.1,2 
Among the 14 patients with pain persisting >12 months, 7 had complete resolution of pain, 5 had persisting 
pain that either improved or remained mild, 1 had ongoing moderate pain at 7 years, and 1 was lost to follow-
up.2 (See Table.) Although postherpetic neuralgia can recur after resolution,4 no recurrence of pain was found 
among 183 randomly selected patients who had had resolution by 1 year.2 
These results are similar to those found in an analysis of a retrospective cohort drawn from a large general 
practice network database,5 as well as other population-based studies.6,7 The prognosis is better than that 
reported in the placebo arms of trials of acute herpes zoster treatment.4 Patients in such trials are more likely 
to have severe disease than those seen in primary care settings. 
 
TABLE 
Risk of postherpetic neuralgia by age 
Age (y) Pain at 3 mo Pain at 1 y 
>50 3% mild 0% 
50–59 4% mild 4% mild 
60–69 9% mild 3% mild 
  4% moderate to severe 1% moderate 
≥70 18% mild 8% mild 
  6% moderate to severe 2% moderate 
  RECOMMENDATIONS FROM OTHERS 
A British guideline states that 5% of herpes zoster patients have postherpetic neuralgia 1 year after shingles.8 
A review in the New England Journal of Medicine states that 48% of herpes zoster patients aged >70 years 
have postherpetic neuralgia at 1 year.9 This prevalence comes from a retrospective cohort study that combined 
patients presenting to a referral center with herpes zoster or postherpetic neuralgia into a single cohort, thus 
overestimating the prevalence of postherpetic neuralgia and providing a less reliable prognosis.10 
CLINICAL COMMENTARY 
Larry  Halverson,  MD 
Cox Health Systems Family Practice Residency Program,Springfield, Missouri 
Knowing the overall good prognosis for postherpetic neuralgia is helpful as I encounter 
patients with shingles. This answer is consistent with my experience. Fear of potential 
interminable pain and anecdotal experience with prolonged patient suffering has seduced 
me to start medications to “prevent” this problem. In some cases, my unnecessary (and 
unproven) “preventive” medications have produced new problems. Future research should 
focus on effective pain treatment options instead of prevention of a condition that usually 
resolves with time. 
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